A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

Completed · Phase 1/Phase 2

Conditions studied: Select Advanced Malignancies, Kidney Cancer, Clear Cell Renal Cell Carcinoma

In brief

To evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Participants with Select Advanced Malignancies.

Key facts

Study ID

NCT02118337

Run by

MedImmune LLC

People needed

97

Starts

2014-05-19

Expected to finish

2020-03-17

Last updated by the study team

2021-06-01

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must be 18 years or older
• Eastern Cooperative Oncology Group performance status of 0-1
• Adequate organ function
• At least 1 prior line of therapy

You may not qualify if…

• Concurrent enrollment in another clinical study, unless in follow-up period or it is an observational study
• Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
• Prior treatment with immunotherapy

Where it is running

• Research Site — Los Angeles, California, United States
• Research Site — Tampa, Florida, United States
• Research Site — Overland Park, Kansas, United States
• Research Site — Louisville, Kentucky, United States
• Research Site — Rochester, Minnesota, United States
• Research Site — Hackensack, New Jersey, United States
• Research Site — New York, New York, United States
• Research Site — Cleveland, Ohio, United States
• Research Site — Oklahoma City, Oklahoma, United States
• Research Site — Portland, Oregon, United States
• Research Site — Hershey, Pennsylvania, United States
• Research Site — Nashville, Tennessee, United States
• Research Site — Seattle, Washington, United States
• Research Site — East Bentleigh, Australia
• Research Site — Frankston, Australia
• Research Site — Toronto, Ontario, Canada
• Research Site — Montreal, Quebec, Canada
• Research Site — Bordeaux, France
• Research Site — Dijon, France
• Research Site — Marseille, France
• Research Site — Paris, France
• Research Site — Villejuif, France
• Research Site — Amsterdam, Netherlands
• Research Site — Groningen, Netherlands
• Research Site — Cambridge, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.